title: Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice.
abstract: OBJECTIVE
  The purposes of our study were to evaluate the effect of intraperitoneal albendazole on tumor growth, ascites formation, and vascular endothelial growth factor (VEGF) mRNA expression, and to assess the synergistic effect of paclitaxel in OVCAR-3-bearing nude mice.
  
  
  METHODS
  In all, 4 groups of mice were injected intraperitoneally with weekly albendazole (450 mg/kg per week), paclitaxel (30 mg/kg per week), albendazole plus paclitaxel, or normal saline for 4 weeks.
  
  
  RESULTS
  Ascitic fluid accumulation (2.47, 2.65, 2.88, and 5.90 mL, respectively) and in ascitic VEGF levels were significantly reduced in the 3 treatment groups compared to the control group (170.83, 229.16, 267, and 1625 pg/mL, respectively). However, complete tumor suppression was more prominent in the paclitaxel group, and VEGF mRNA expression was more strongly inhibited in the albendazole group (P < .05). No synergistic effect of albendazole and paclitaxel was observed.
  
  
  CONCLUSIONS
  We demonstrated a differential effect of albendazole and paclitaxel in a xenograft model of ovarian carcinoma; albendazole suppressed ascites formation by inhibiting VEGF secretion, and paclitaxel exerted its effects by direct cytotoxicity.
authors.affiliation: The Department of Obstetrics and Gynecology, NHIC Ilsan Hospital, Koyang, South Korea.
authors.forename: Eun-Kyoung
authors.initials: EK
authors.lastname: Choi
authors.forename: Sang-Wun
authors.initials: SW
authors.lastname: Kim
authors.forename: Eun-Ji
authors.initials: EJ
authors.lastname: Nam
authors.forename: Jiheum
authors.initials: J
authors.lastname: Paek
authors.forename: Ga-Won
authors.initials: GW
authors.lastname: Yim
authors.forename: Myeong-Hwa
authors.initials: MH
authors.lastname: Kang
authors.forename: Young-Tae
authors.initials: YT
authors.lastname: Kim
mesh_terms: D015766:Albendazole / Q000008:administration & dosage; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D001201:Ascites / Q000378:metabolism; D005260:Female; D051379:Mice; D008819:Mice, Nude; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D017239:Paclitaxel / Q000008:administration & dosage; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D050257:Tubulin Modulators / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D012333:RNA, Messenger; D050257:Tubulin Modulators; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D015766:Albendazole; D017239:Paclitaxel